Navigation Links
Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
Date:5/15/2008

- Unprecedented amount of research reflects depth and breadth of collaboration with investigators worldwide to develop new treatments for

diverse forms of cancer

- Plenary session to highlight impact of Zometa(R), the leading IV bisphosphonate, on relapse rate of patients with early-stage breast cancer - Four oral sessions to feature RAD001, first oral once-daily continuous inhibitor of mTOR, including first results of RECORD-1 study in renal cell

carcinoma

- Updated Phase II results with Tasigna(R) in Philadelphia

chromosome-positive chronic myeloid leukemia to be presented

EAST HANOVER, N.J., May 15 /PRNewswire/ -- Novartis Oncology announced today that the 44th annual meeting of the American Society of Clinical Oncology (ASCO) will include an unprecedented amount of research drawing from Novartis Oncology's robust pipeline of investigational compounds and existing cancer therapies. Novartis Oncology's cancer therapies will be the subject of more than 170 abstracts at the meeting, and will be highlighted in a plenary session, as well as seven oral presentations.

A plenary session will feature the first efficacy results from the ABCSG-12 study, looking at the impact of Zometa(R) (zoledronic acid) on disease-free survival in patients with early-stage breast cancer (Abstract #LBA4: Sunday, June 1, 2008; 1:45 PM to 2:00 PM CDT). In addition, late-breaking data on the role of RAD001 (everolimus) as a potential new treatment option for patients with advanced kidney cancer who have failed standard therapies will be presented in an oral session (Abstract #LBA5026: Saturday, May 31, 2008; 4:30 PM-4:45 PM CDT).

"This is a particularly exciting year for Novartis Oncology in advancing research and touching the lives of thousands of cancer patients," said David Epstein, CEO & President of Novartis Oncology. "Our scientific presence at ASCO shows that N
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
2. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
3. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
4. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
5. Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation
6. Inverness Medical Innovations to Present at CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007
9. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... ANGELES , July 21, 2014 /PRNewswire/ ... Agency (LOPA) is utilizing the CompuMed, Inc. ... Solution to improve donor organ recovery. CompuMed ... to provide real-time access to its Board-Certified ... care consulting.      (Logo: http://photos.prnewswire.com/prnh/20140721/697628) ...
(Date:7/21/2014)... AVIV, Israel , July 21, 2014 ... a clinical-stage biopharmaceutical company focused on the development and ... of liver diseases and cholesterol gallstones, announced today that ... Friday, July 25, 2014 to discuss results for the ... update on current developments with respect to its clinical ...
(Date:7/21/2014)... 21, 2014 Integrity Applications, Inc. (OTCQB: ... GlucoTrack ® model DF-F noninvasive blood glucose ... through its wholly-owned subsidiary, Integrity Applications Ltd., into ... arm of Acer Inc.  Pursuant to the agreement, ... a non-exclusive basis) the GlucoTrack Model DF-F and ...
Breaking Medicine Technology:Louisiana Organ Procurement Agency Leveraging CompuMed to Secure More Donor Hearts 2Louisiana Organ Procurement Agency Leveraging CompuMed to Secure More Donor Hearts 3Galmed Pharmaceuticals Second Quarter 2014 Conference Call and Webcast Scheduled for Friday, July 25, 2014 2Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 2Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 3
... N.J., Sept. 13 Soligenix, Inc. (Soligenix or the ... late-stage biopharmaceutical company, announced today that its President and ... a company overview highlighting recent developments at the Rodman ... City.  The presentation will take place on Wednesday, September ...
... Sutter Health today announced a donation of $100,000 to the ... in relief efforts following a destructive fire in San Bruno ... is made on behalf of the Northern California network,s employees, ... donated by Sutter-affiliated California Pacific Medical Center (CPMC). ...
Cached Medicine Technology:Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT 2Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT 3Sutter Health Network Donates $150,000 to Aid Victims of San Bruno Fire 2
(Date:7/22/2014)... July 22, 2014 Getting breast implants is ... completely optional or due to medical necessity. Either way, women ... to prepare for it, says Robert Kraft, MD, Plastic Surgeon ... implant removal surgeries are performed each year in the United ... 70 percent of those procedures stem from three main problems: ...
(Date:7/22/2014)... Southlake, TX (PRWEB) July 22, 2014 ... proving to address skin laxity with results that are ... opposed to topically treating the skin with radio frequency, ... probes which are inserted under the skin to “inject” ... studies have shown that this single treatment solution for ...
(Date:7/21/2014)... (PRWEB) July 22, 2014 On Monday, September ... Charity Golf Outing honoring Mike McGuriman-Motorola Solutions at The Knoll ... outing begins with registration and lunch at 11 a.m. ... and prizes. Price increases to $250 after September 7th. ... for $100 per person. The dinner will include a ...
(Date:7/21/2014)... (PRWEB) July 21, 2014 PowerObjects, ... service, support, education, and add-ons for Microsoft Dynamics ... Inner Circle, an elite group of the most ... with sales achievements that rank them in the ... of partners. Members of the Microsoft Dynamics Inner ...
(Date:7/21/2014)... human nature to hate losing. , Unfortunately, it,s ... abandoning a solid strategy and thus increasing your chances ... conclusion of a Brigham Young University study published this ... finding is based on an analysis of two decades ... focused on whether coaches adjusted their personnel following games ...
Breaking Medicine News(10 mins):Health News:Is Breast Implant Removal Right for You? Plastic Surgeon Dr. Robert Kraft With Advanced Dermatology, PC Explains Breast Implant Removal and Offers Tips On Procedure 2Health News:Is Breast Implant Removal Right for You? Plastic Surgeon Dr. Robert Kraft With Advanced Dermatology, PC Explains Breast Implant Removal and Offers Tips On Procedure 3Health News:New Minimally Invasive Procedure, ThermiTight, “Injects” Radio Frequency to Treat Skin Laxity 2Health News:7th Annual Push to Walk Golf Outing to Be Held September 22nd 2Health News:PowerObjects Joins the 2014 Microsoft Dynamics Inner Circle 2Health News:'Moral victories' might spare you from losing again 2
... HealthDay Reporter , TUESDAY, May 17 (HealthDay News) ... birth defects in women taking these drugs during the first ... the drugs are relatively new, further studies are needed to ... In a large study of children born in Denmark, ...
... City, the prevalence of asthma among children entering school ... children growing up within walking distance of each other ... asthma. In the first comprehensive effort to understand ... Mailman School of Public Health compared the household presence ...
... . , Pediatric and young adult leukemia and ... the Cole Foundation,s announcement that it would provide more than ... four McGill University young scientists. "The Cole Foundation is dedicated ... the age of 25, and the research projects we finance ...
... from Boston University School of Medicine (BUSM) have discovered ... syndromes. The team connected pharmacological properties of the Novartis ... for the first time after investigating adverse reactions suffered ... treatment of osteoporosis. These findings appear online in the ...
... -- A gene variation that causes faulty cholesterol regulation also ... may be a reason why some women can,t get pregnant, ... more than 200 infertile women who were undergoing in vitro ... the scavenger receptor class B type 1 (SCARB1) gene. ...
... the intermittent interruption of breathing that occurs in patients with ... cells and increased tumor growth in mice, according to researchers ... mouse models tended to contain more dead cells, indicating a ... the study will be presented at the ATS 2011 International ...
Cached Medicine News:Health News:Newer Epilepsy Meds Less Likely to Cause Birth Defects: Study 2Health News:Newer Epilepsy Meds Less Likely to Cause Birth Defects: Study 3Health News:Cockroach allergens in homes associated with prevalence of childhood asthma in some neighborhoods 2Health News:Cole Foundation injects $700,000 into childhood cancer research 2Health News:Gene Variation May Explain Some Female Infertility Cases 2Health News:Obstructive sleep apnea linked to cancer growth in mice 2Health News:Obstructive sleep apnea linked to cancer growth in mice 3
... Helmer PC1200 Platelet Incubators ... your laboratory counter top. These ... institution to have the security ... environment without taking up a ...
The PC4200i is the largest capacity platelet incubator available. It features a built-in agitator with a capacity of 396 random bags (132 apheresis)....
... rotators and agitators for continual ... set at 22C (71F) or ... (59F to 104F). Uniformity is ... bottom. Recorder is standard on ...
An enzyme-linked immuno-sorbent assay for the detection and quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Medicine Products: